A Phase 1, Single-Center, Open-Label, 2-Cohort Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Midomafetamine at Therapeutic and Supratherapeutic Doses
Phase: PHASE1 | Sponsor: Resilient Pharmaceuticals | Compound: Psychedelic
- Status
- active
- Institution
- Resilient Pharmaceuticals
- Start date
- 2026-04-23
- End date
- 2026-07-30
- Registry ID
- NCT07584720
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.